Ceva Completes Deal to Acquire Portfolio of Merial Swine and Cattle Vaccines and Nonsteroidal Anti-inflammatories from Boehringer Ingelheim

Food and Healthcare Press Releases Friday January 20, 2017 10:34
LIBOURNE, France--20 Jan--PRNewswire/InfoQuest

Ceva Sante Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim following its acquisition of Merial Animal Health.

All the products will be immediately available through local Ceva companies or its distributors, with no interruption of supply.
Ceva has been consistently one of the fastest growing top 10 veterinary businesses in the last decade, investing heavily in the development of vaccines, as part of its global preventative health strategy.
Commenting on the deal, Ceva Chairman & CEO Dr. Marc Prikazsky said:

"We are delighted to acquire this range of products and strong pipeline of R&D assets.   The knowhow behind these products dates from Pasteur, Rhone-Merieux, Merial and now as Ceva we are conscious that we have a responsibility to maintain this strong veterinary scientific tradition.   Our customers can be assured that we will continue to invest to develop the products of both today and tomorrow."

ABOUT CEVA SANTE ANIMALE

Ceva Sante Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne (Gironde). Ceva Chairman and CEO is Marc Prikazsky.

Website: http://www.ceva.com
PRESS CONTACT
Martin Mitchell
Communication Director
+33-05-57-55-40-80
martin.mitchell@ceva.com
Company: Davidson Ryan Dore
Lawrence Dore
Lawrence.dore@drdpartnership.com
Phone: +44(0)207-520-9218
Source: Ceva Sante Animale

Latest Press Release

Novo Nordisk (Thailand) is hosting a press conference for the topic of Rethink Obesity.

Mr. John Dawber, Vice President and General Manager at Novo Nordisk (Thailand) is hosting a press conference for the topic of "Rethink Obesity". The event will be chaired by His Excellency Mr. Uffe Wolffhechel, Ambassador of Denmark to Thailand, and will...

Brain Health Supplements Market Expecting an Outstanding Growth Till 2025

The global brain health supplements market size is expected to reach USD 10.7 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.2% over the forecast period. Growing health concerns over depression, anxiety,...

Menarini Silicon Biosystems Launches VRNxT Volume Reduction Instrument

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, announced that it will launch the new VRNxT(TM), a volume reduction instrument optimized to remove manual sample volume reduction steps in cellular biology...

BREASTFEEDING CAMPAIGN SETS A NEW REGIONAL STANDARD FOR SUSTAINABLE COMMUNICATION

The "6 months mother's milk is all you need" campaign has been awarded South East Asia PR Campaign of the year and Cause related public awareness campaign of the Year by Campaign Asia at the PR awards in Hong Kong last month. Initiated by Save The...

Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of NABOTA

Daewoong Pharmaceutical Co., Ltd, a world-leading botulinum toxin manufacturer in Korea, announced its participation in IMCAS Asia 2019 held in Bali, Indonesia July 5-7, 2019 to introduce the excellence of NABOTA(R) (Prabotulinumtoxin A). The 13th year...

Related Topics